Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas

Journal of Neuro-Oncology

Volumn 65, Issue 3, 2003, Pages 203-226

  Shah, Amish C ^a   Benos, Dale ^a   Gillespie, G Yancey ^a   Markert, James M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

Author keywords

Clinical trials; G207; Gene therapy; HSV 1716; Malignant glioma; Newcastle virus; Oncolytic; ONYX 015 adenovirus; Poliovirus replicon; Reovirus; Vaccinia

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CISPLATIN; CN706 PROTEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOKINE; DEXAMETHASONE; FLUOROURACIL; G207 PROTEIN; GANCICLOVIR; GENE PRODUCT; HSV1716 PROTEIN; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 4; M002 PROTEIN; MITOMYCIN; NV1020 PROTEIN; ONCOLYTIC VIRUS; ONYX 015; PHENYTOIN; PV701 PROTEIN; R3616 PROTEIN; R3659 PROTEIN; R4009 PROTEIN; R8306 PROTEIN; REOLYSIN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ONCOLYSATE; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CELL MANIPULATION; CLINICAL TRIAL; CRANIOTOMY; DOSE CALCULATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GENE EXPRESSION; GLIOMA; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HUMAN; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; POLIOMYELITIS VIRUS; RECURRENT CANCER; REOVIRUS; REPLICON; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SUICIDE GENE THERAPY; TREATMENT FAILURE; TUMOR CELL DESTRUCTION; VACCINATION; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS MUTANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; REOVIRIDAE; VIRUSES;

EID: 0346873921     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000003651.97832.6c     Document Type: Review

References (148)

1. Rainov NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Human Gene Ther 11: 2389-2401, 2000
2. De Pace NG: Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica. Ginecologia 9: 82-88, 1912
3. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 6(9): 1211-1218, 1956
4. Bluming AZ and Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet 105-107, 1971
5. Taqi AM: Regression of Hodgkin's disease after measles. Lancet 1(8229): 1112, 1981
6. Pasquinucci G: Possible effect of measles on leukaemia. Lancet 1(7690): 136, 1971
7. Gross S: Measles and leukaemia. Lancet 1(7695): 397-398, 1971
8. Asada T: Treatment of human cancer with mumps virus. Cancer 34: 1907-1928, 1974
9. Okuno Y, Asada T, Yamanishi K, Otsuka T, Takahashi M, Tanioka T, Aoyama H, Fukui O, Matsumoto K, Uemura F, Wada A: Studies on the use of mumps virus for treatment of human cancer. Biken J 21(2): 37-49, 1978
10. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991
11. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7(10): 867-874, 2000
12. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866, 2000
13. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB, Eckhardt SG: A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806, 2000
14. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 60(22): 6359-6366, 2000
15. Chou J, Kern ER, Whitley RJ, Roizman B: Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250(4985): 1262-1266, 1990
16. Goldstein DJ and Weller SK: Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196-205, 1988
17. 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. PNAS 94: 843-848, 1997
18. 134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells form triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cell. PNAS 89: 3266-3270, 1992
19. Farassati F, Yang A, Lee PWK: Oncogenesis in Ras signaling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nature Cell Biol 3: 745-750, 2001
20. Whitley Kern ER, Chatterjee S, Chou J, Roizman B: Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Investigation 91: 2837-2843, 1993
21. Goldstein DJ, Weller SK: Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 166: 41-51, 1988
22. Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54: 3963-3966, 1991
23. Coen DM, Goldstein DJ, Weller SK: Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother 33: 1395-1399, 1989
24. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1: 938-943, 1995
25. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. PNAS 92(5): 1411-1415, 1995
26. Markert JM, Malick A, Coen DM, Martuza RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurg 32(4): 597-603, 1993
27. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J Virol 74(8): 3832-3841, 2000
28. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol 73(8): 6319-6326, 1999
29. Valyi-Nagy T, Fareed MU, O'Keefe JS, Gesser RM, MacLean AR, Brown SM, Spivack JG, Fraser NW: The HSV-1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 75: 2059-2063, 1994
30. Randazzo RB, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, Maclean A, Fraser NW: Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211(1): 94-101, 1995
31. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM, Trojanowski JQ, Fraser NW: Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 73(5): 636-648, 1995
32. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, Harland J, Mabbs R, Brown M: The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoral injection into human malignant glioma: A proof of principle study. Gene Ther 9(6): 398-406, 2002
33. Harland J, Papanastassiou V, Brown SM: HSV1716 persistence in primary human glioma cells in vitro. Gene Ther 9: 1194-1198, 2002
34. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, Weichselbaum RR: Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5(2): 160-165, 1998
35. Bradley JD, Kataoka Y, Advani S, Chung SM, Arani RB, Gillespie GY, Whitley RJ, Markert JM, Roizman B, Weichselbaum RR: Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Canc Res 5: 1517-1522, 1999
36. Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL: Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Human Gene Ther 13(5): 627-639, 2002
37. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ: Genetically engineered HSV in the treatment of glioma: A review. Rev Med Virol 10(1): 17-30, 2000
38. Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1(2): 162-169, 1999
39. Toda M, Rabkin SD, Martuza RL: Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9(15): 2177-2185, 1998
40. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). GASEB J 13(11): 1325-1334, 1999
41. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL: Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10(13): 2237-2243, 1999
42. Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y: Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 53(2): 95-100, 2002
43. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y: Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 4(6): 580-588, 2000
44. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y: Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 10(10): 1599-1606, 1999
45. Wong RJ, Kim S, Joe JK, Shah JP, Johnson PA, Fong Y: Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193(1): 12-21, 2001
46. Fong Y, Kemeny N, Jarnagin W, Stanziale S, Guilfoyle B, Gusani N, Joe J, Blumgart L, Lakeman F, Gammon K, Perterkin J, Horsburgh B, Tufaro F: Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Amer Soc Clin Oncol (URL: www.sco.org), 2002 (Abstract 27)
47. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5(1): 121-130, 1998
48. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM: Engineered herpes simplex virus expression IL-12 in the treatment of experimental murine brain tumors. PNAS 97(5): 2208-2213, 2000
49. Chase M, Chung R, Chiocca EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol 16: 444-448, 1998
50. Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, Chiocca EA: Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res 61(3): 864-868, 2001
51. Wei MX, Tamiya T, Rhee RJ, Breakefield SO, Chiocca EA: Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cycloposphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1: 1171-1177, 1995
52. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkestein D, Harsh GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral resonses. Nature Med 5(8): 881-887, 1999
53. Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S, Chiocca EA, Tanabe KK: Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant the expresses the CYP2B1 transgene. Cancer 95(5): 1171-1181, 2002
54. Fields BN, Kinipe DM, and Howley PM: Fundamental Virology: 3rd edn. Lippincott Williams and Wilkins, Philadelphia, 1996, pp 44-45
55. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57(13): 2559-2563, 1997
56. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7: 120-126, 2001
57. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996
58. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211-1218, 1956
59. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156: 107-121, 1987
60. Hall A, Dix BR, O'Carroll SJ, Braithwaite AW: p53-Dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med 4: 1068-1072, 1998
61. Goodrum F, Ornelles D: p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 72: 9479-9490, 1998
62. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Zur Hausen H: Replication of ONYX-015, a potential anti-cancer adenovirus is independent of p53 status in tumor cells. J Virol 72: 9470-9478, 1998
63. Harda JN, Berk AJ: p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 73(7): 5333-5344, 1999
64. Hay JG, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom WN: Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene. Human Gene Ther 10(4): 579-590, 1999
65. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 3(6): 639-645, 1997
66. Kirn DH: Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 8: 89-98, 2001
67. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D: Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 7(22): 1925-1929, 2000
68. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Fuenteun J, Kirn DH, Vassal G: Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62(3): 764-772, 2002
69. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH: A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med 6(8): 879-885, 2000
70. Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P: Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nature Biotechnol 19(11): 1035-1041, 2001
71. Mayol X, Garriga J, Grana X: Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene 11(4): 801-808, 1995
72. Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B, Pestell RG: Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol 18(2): 3212-3222, 1998
73. Hamel W, Westphal M, Shepard HM: Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neuro-Oncology, 16(2): 159-165, 1993
74. Whyte P, Ruley HE, Harlow E: Two regions of the adenovirus early region 1A proteins are required for transformation. J Virol 62(1): 257-265, 1998
75. Whyte P, Williamson NM, Harlow E: Cellular targets for transformation by the adenovirus E1A proteins. Cell 56: 67-75, 1989
76. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Med 6(10): 1134-1139, 2000
77. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1): 2-12, 2000
78. Suzuki K, Alemany R, Yamamoto M, Curiel DT: The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 8(11): 3348-3359, 2002
79. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ: Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286: 1568-1571, 1999
80. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG: Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Human Gene Ther 12(10): 1323-1332, 2001
81. Sauthoff H, Heitner S, Rom WN, Jay JG: Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 11(3): 379-388, 2000
82. Sauthoff H, Pipiya T, Heitner S, Chen S, Norman RG, Rom WN, Hay JG: Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 13(15): 1859-1871, 2002
83. Lamfers ML, Grill J, Driven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, Alemany R, Fueyo J, Curiel DT, Vassal G, Pinedo HM, Vandertop WP, Gerritsen WR: Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62(20): 5736-5742, 2002
84. Alexander DJ, Allan WH: Newcastle disease virus pathotypes. Avian Path 3(4): 269-278, 1974
85. Schirrmacher V, Griesbach A, Ahlert T: Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int J Oncol 18(5): 945-952, 2001
86. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52(5): 448-453, 1992
87. Wheelock EF, Dingle JH: Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. NEJM 271(13): 645-651, 1964
88. Cassel WA, Garret RE: Newcastle disease virus as an antineoplastic agent. Cancer 18(7): 863-868, 1965
89. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by Reovirus. EMBO J 17: 3351-3362, 1998
90. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Canc Res 54(23): 6017-6021, 1994
91. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME: Complete regression of human neuroblastoma xenografts in athymic mice after local Newscastle disease virus therapy. J Natl Canc Inst 86(16): 1228-1233, 1994
92. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ: Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett 172(1): 27-36, 2001
93. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251-2266, 2002
94. Csatary LK: Viruses in the treatment of cancer: Letter to the editor. Lancet 2(7228): 825, 1971
95. Csatary LL, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T: Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 19(1B): 635-638, 1999
96. Castary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary CM: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17(6): 619-627, 1993
97. Csatary LK, Bakacs T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281(17): 1588-1589, 1999
98. Schirrmacher V, Ahlert T, Probstle T, Steiner HH, Herold-Mende C, Gerhards R, Hagmuller E, Steiner HH: Immunization with virus-modified tumor cells. Semin Oncol 25(6): 677-696, 1998
99. Haas C, Ertel C, Gerhards R, Schirrmacher V: Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle disease virus. Int J Oncol 13(6): 1105-1115, 1998
100. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J: Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9(3): 225-235, 1994
101. Lorence RM, Rood PA, Kelley KW: Newcastle disease virus as an antineoplastic agent: Introduction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Canc Inst 80(16): 1305-1312, 1988
102. Cassel WA, Murras DR, Torbin AH, Olkowski ZL, Moore ME: Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 40(2): 672-679, 1977
103. Murray DR, Cassel WA, Torbin AH, Olkowski ZL, Moore ME: Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer 40(2): 680-686, 1977
104. Cassel WA, Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9(4): 169-171, 1992
105. Plager C, Bowen JM, Fenoglio C: Adjuvant immunotherapy of M.D. Anderson hospital (MDAH) stage III-B malignant melanoma with Newcastle disease virus oncolysate. Proc Am Soc Clin Oncol 9: 281, A1091, 1990
106. Kirchner HH, Anton P, Atzpodien J: Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13(3): 171-173, 1995
107. Mallmann P, Eis-Hübinger AM, Krebs D: Lymphokine-activated tumor-infiltrating lymphocytes and autologous tumor vaccine in breast and ovarian cancer. Onkologie 15: 490-496, 1992
108. Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37(4): 569-577, 1986
109. Ahlert T, Sauberbei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Hacker B, Schumacher M, Schirrmacher V: Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15(4): 1354-1366, 1997
110. Pomer S, Schirrmacher V, Thiele R, Löhrke H, Staehler G: Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-alpha2b. Int J Oncol 6: 947-954, 1995
111. Liebrich W, Schlag P, Manasterski M, Lehner B, Stohr M, Moller P, Schirrmacher V: In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 27 (6): 703-710, 1991
112. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V: Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 35(3): 325-330, 1992
113. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmuller E, Buchcik R, Nagel M, Saeger HD: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2(1): 21-28, 1996
114. Fields BN, Kinipe DM, Howley PM: Fundamental Virology: 3rd edn. Lippincott Williams and Wilkins, Philadelphia, 1996, pp 691-693
115. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15(23): 2755-2765, 1997
116. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. PNAS 91(16): 7729-7731, 1994
117. Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B: Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 266(25): 16755-16763, 1991
118. Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated as pathway. Science 282: 1332-1334, 1998
119. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA: Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Canc Inst 93(12): 903-912, 2001
120. Gromeier M, Alexander L, Wimmer E: Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. PNAS 93: 2370-2375, 1996
121. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E: Dual stem loops within the polyvirus internal ribosomal entry site control neurovirulence. J Virol 73: 958-964, 1999
122. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E: Intergeneric poliovirus recombinants for the treatment of malignant glioma. PNAS 12: 6803-6808, 2000
123. Mendelsohn CL, Wimmer E, Racaniello VR: Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56: 855-865, 1989
124. Hagino-Yamagishi K, Nomoto A: In vitro construction of poliovirus defective interfering particles. J Virol 63(12): 5386-5392, 1989
125. Ansardi DC, Porter DC, Morrow CD: Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans. J Virol 67(6): 3684-3690, 1983
126. Ansardi DC, Porter DC, Morrow CD: Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J Virol 65(4): 2088-2092, 1991
127. Porter DC, Ansardi DC, Morrow CD: Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans. J Virol 69(3): 1548-1555, 1994
128. Ansardi DC, Porter DC, Jackson CA, Gillespie GY, Morrow CD: RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res 61(23): 8470-8479, 2001
129. Bledsoe AW, Gillespie GY, Morrow CD: Targeted foreign gene expression in spinal cord neurons using poliovirus replicons. J Neurovirol 6(2): 95-105, 2000
130. Jackson CA, Cobbs C, Peduzzi JD, Novak M, Morrow CD: Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis. Human Gene Ther 12(15): 1827-1841, 2001
131. URL: http://www.replicontechnologies.com/Technology.htm
132. Ansardi DC, Moldoveanu Z, Porter DC, Walker DE, Conry RM, LoBuglio AF, McPherson S, Morrow CD: Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res 54(24): 6359-6364, 1994
133. Porter DC, Ansardi DC, Wang J, McPherson S, Moldoveanu Z, Morrow CD: Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase. Virology 243: 1-11, 1998
134. Bledsoe AW, Jackson CA, McPherson S, Morrow CD: Cytokine production in motor neurons by poliovirus replicon vector gene delivery. Nature Biotechnol 18(9): 964-969, 2000
135. Basak S, McPherson S, Kang S, Collawn JF, Morrow CD: Construction and characterization of encapsidated poliovirus replicons that express biologically active murine interleukin-2. J Interferon Cytokine Res 5: 305-313, 1998
136. Fields BN, Knipe DM, Howley PM: Fields Virology: 3rd edn. Lippincott-Raven, Philadelphia, 1996, p1163.
137. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187(1): 69-79, 1998
138. Gridley DS, Andres ML, Li J, Timiryasova T, Chen B, Fodor I: Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol 13(5): 1093-1098, 1998
139. Timiryasova TM, Chen B, Haghighat P, Fodor I: Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 14(5): 845-854, 1999
140. Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, Fodor I: Antitumor effect of vaccinia virus in glioma model. Oncol Res. 11(3): 133-44, 1999
141. Chen B, Timiryasova TM, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I: Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther 7(11): 1437-1447, 2000
142. Chen B, Timiryasova TM, Haghighat P, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I: Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 24(1): 46-57, 2001
143. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B: Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317(6040): 813-815, 1985
144. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL: Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 10(4): 649-657, 1999
145. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61(24): 8751-8757, 2001
146. Heise C, Lemmon M, Kirn D: Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 6(12), 4908-4914, 2000
147. Fields BN, Knipe DM, Howley PM: Fields Virology: 3rd edn. Lippincott-Raven, Philadelphia, 1996, p2116
148. Kundaje A, Eisenman S: (URL): http://www.cs.columbia.edu/~abk2001/cellcycle.pdf. Modeling of the p53 pathway to cell cycle arrest and apoptosis: Relevance to cancer. 1-19, 2001